Patents by Inventor Robert F. Graziano

Robert F. Graziano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL-10 AND USES THEREOF
    Publication number: 20230087600
    Abstract: The present disclosure provides fusion proteins comprising an IL-10 polypeptide and a second polypeptide, e.g., an Fc polypeptide. Certain aspects of the present disclosure are directed to methods of treating a subject comprising administering the IL-10 fusion protein. In certain aspects, the subject is afflicted with a cancer.
    Type: Application
    Filed: February 5, 2021
    Publication date: March 23, 2023
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Shodeinde COKER, Robert F. GRAZIANO, Murali GURURAJAN, Kanstantsin V. KATLINSKI, James K. LOY, Paul E. MORIN, Brian A. POIRSON, Vanessa M. SPIRES, Zheng YANG
  • ANTIBODIES AGAINST MICA AND/OR MICB AND USES THEREOF
    Publication number: 20220281980
    Abstract: The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.
    Type: Application
    Filed: January 24, 2022
    Publication date: September 8, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Michelle Renee KUHNE, Alan J. KORMAN, Haichun HUANG, Yiming YIN, Robert F. GRAZIANO, Natalie A. BEZMAN, Pavel STROP, Richard Y. HUANG, Guodong CHEN, Mohan SRINIVASAN, Peter Sung Keun LEE, Gamze Ozlem CAMDERE
  • USE OF ANTI-CTLA-4 ANTIBODIES WITH ENHANCED ADCC TO ENHANCE IMMUNE RESPONSE TO A VACCINE
    Publication number: 20220127363
    Abstract: The present invention provides methods of enhancing immune response to a vaccine using variant forms of anti-CTLA-4 antibodies having enhanced ADCC activity. Variant anti-CTLA-4 antibodies for use in the present invention include nonfucosylated ipilimumab.
    Type: Application
    Filed: January 13, 2022
    Publication date: April 28, 2022
    Inventors: John T. LOFFREDO, Katherine E. LEWIS, Robert F. GRAZIANO, Alan J. KORMAN
  • Antibodies against MICA and/or MICB and uses thereof
    Patent number: 11242393
    Abstract: The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: February 8, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michelle Renee Kuhne, Alan J. Korman, Haichun Huang, Yiming Yin, Robert F. Graziano, Natalie A. Bezman, Pavel Strop, Richard Y. Huang, Guodong Chen, Mohan Srinivasan, Peter Sung Keun Lee, Gamze Ozlem Camdere
  • Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
    Patent number: 10688180
    Abstract: Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: June 23, 2020
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, INNATE PHARMA
    Inventors: Robert F. Graziano, Ashok K. Gupta, Su Young Kim, Jon Wigginton, Pascale Andre
  • USE OF ANTI-CTLA-4 ANTIBODIES WITH ENHANCED ADCC TO ENHANCE IMMUNE RESPONSE TO A VACCINE
    Publication number: 20190382490
    Abstract: The present invention provides methods of enhancing immune response to a vaccine using variant forms of anti-CTLA-4 antibodies having enhanced ADCC activity. Variant anti-CTLA-4 antibodies for use in the present invention include nonfucosylated ipilimumab.
    Type: Application
    Filed: February 27, 2018
    Publication date: December 19, 2019
    Inventors: John T. LOFFREDO, Katherine E. LEWIS, Robert F. GRAZIANO, Alan J. KORMAN
  • ANTIBODIES AGAINST MICA AND/OR MICB AND USES THEREOF
    Publication number: 20190315870
    Abstract: The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.
    Type: Application
    Filed: March 22, 2019
    Publication date: October 17, 2019
    Applicant: Bristol-Myers Squibb Company
    Inventors: Michelle Renee KUHNE, Alan J. KORMAN, Haichun HUANG, Yiming YIN, Robert F. GRAZIANO, Natalie A. BEZMAN, Pavel STROP, Richard Y. HUANG, Guodong CHEN, Mohan SRINIVASAN, Peter Sung Keun LEE, Gamze Ozlem CAMDERE
  • COMBINATION OF ANTI-KIR AND ANTI-CTLA-4 ANTIBODIES TO TREAT CANCER
    Publication number: 20180117147
    Abstract: Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.
    Type: Application
    Filed: September 13, 2017
    Publication date: May 3, 2018
    Inventors: Robert F. GRAZIANO, Ashok K. GUPTA, Su Young KIM, Jon WIGGINTON, Pascale ANDRE
  • COMBINATION OF ANTI-KIR ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREAT CANCER
    Publication number: 20180099045
    Abstract: Provided are methods for clinical treatment of cancer (e.g., advanced refractory solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-PD-1 antibody.
    Type: Application
    Filed: October 12, 2017
    Publication date: April 12, 2018
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Robert F. GRAZIANO, Ashok K. GUPTA, Su Young KIM, Jon WIGGINTON
  • COMBINATION OF ANTI-CS1 AND ANTI-PD1 ANTIBODIES TO TREAT CANCER (MYELOMA)
    Publication number: 20170355768
    Abstract: The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of anti-CS1 antibodies in combination with an anti-Programmed Death-1 (PD-1) antibody.
    Type: Application
    Filed: December 3, 2015
    Publication date: December 14, 2017
    Inventors: Michael Darron ROBBINS, Robert F. Graziano, Natalie Bezman
  • Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
    Patent number: 9789182
    Abstract: Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: October 17, 2017
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, INNATE PHARMA
    Inventors: Robert F. Graziano, Ashok K. Gupta, Su Young Kim, Jon Wigginton, Pascale Andre
  • IMMUNOTHERAPEUTIC DOSING REGIMENS AND COMBINATIONS THEREOF
    Publication number: 20160264670
    Abstract: The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of anti-CS1 antibodies in combination with one or more immunotherapeutic agents.
    Type: Application
    Filed: November 5, 2014
    Publication date: September 15, 2016
    Inventors: Robert F Graziano, Michael Darron Robbins, Maria Jure-Kunkel
  • COMBINATION OF ANTI-KIR ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREAT CANCER
    Publication number: 20150290316
    Abstract: Provided are methods for clinical treatment of cancer (e.g., advanced refractory solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-PD-1 antibody.
    Type: Application
    Filed: October 2, 2013
    Publication date: October 15, 2015
    Inventors: Robert F. Graziano, Ashok K. Gupta, Su Young Kim, Jon Wigginton
  • COMBINATION OF ANTI-KIR AND ANTI-CTLA-4 ANTIBODIES TO TREAT CANCER
    Publication number: 20150283234
    Abstract: Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.
    Type: Application
    Filed: October 23, 2013
    Publication date: October 8, 2015
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Robert F. Graziano, Ashok K. Gupta, Su Young Kim, Jon Wigginton, Pascale Andre
  • Methods of treatment using CTLA-4 antibodies
    Patent number: 8142778
    Abstract: The present invention provides method of treatment using human sequence antibodies against human CTLA-4 linked to a cytotoxic agent. In particular, methods of treating cancer and autoimmune disease are provided.
    Type: Grant
    Filed: October 7, 2008
    Date of Patent: March 27, 2012
    Assignee: Medarex, Inc.
    Inventors: Thomas Andrew Davis, Tibor P. Keler, Robert F. Graziano, Alan J. Korman
  • Methods Of Treatment Using CTLA-4 Antibodies
    Publication number: 20090117037
    Abstract: The present invention provides method of treatment using human sequence antibodies against human CTLA-4 linked to a cytotoxic agent. In particular, methods of treating cancer and autoimmune disease are provided.
    Type: Application
    Filed: October 7, 2008
    Publication date: May 7, 2009
    Applicant: Medarex, Inc.
    Inventors: Thomas Andrew Davis, Tibor P. Keler, Robert F. Graziano, Alan J. Korman
  • Methods of treatment using CTLA-4 antibodies
    Patent number: 7452535
    Abstract: The present invention provides method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided.
    Type: Grant
    Filed: April 11, 2003
    Date of Patent: November 18, 2008
    Assignee: Medarex, Inc.
    Inventors: Thomas Andrew Davis, Tibor P. Keler, Robert F. Graziano, Alan J. Korman
  • Methods of treatment using CTLA-4 antibodies
    Publication number: 20040005318
    Abstract: The present invention provides method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided.
    Type: Application
    Filed: April 11, 2003
    Publication date: January 8, 2004
    Applicant: Medarex, Inc.
    Inventors: Thomas Andrew Davis, Tibor P. Keler, Robert F. Graziano, Alan J. Korman
  • Scaled multiple function nonlinear FM waveform
    Patent number: 5313214
    Abstract: Scaled multiple function non-linear FM waveforms are generated for use in digitally implemented low frequency radar. The non-linear FM waveforms are generated by combining a plurality of functions, each having varying characteristics, to form a single waveform which has the desirable characteristics of weighted linear FM waveforms without the undesirable attributes due to weighting. Accordingly, the use of the non-linear FM waveform results in an increase in detection range of eight percent over existing linear FM waveforms with no degradation in range resolution.
    Type: Grant
    Filed: April 8, 1993
    Date of Patent: May 17, 1994
    Assignee: Grumman Aerospace Corporation
    Inventors: Robert F. Graziano, Russell Singer